| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC67101 | Ganirelix acetate Featured | Ganirelix acetate is an antagonist of GnRH that competitively antagonizes the gonadotropic GnRH receptor, thereby mutating the pathway and causing rapid and reversible inhibition of gonadotropin (luteinizing hormone LH and follicle stimulating hormone FSH) secretion. Ganirelix Acetate acts by competitively blocking the GnRH receptors on the pituitary gonadotroph and subsequent transduction pathway. It induces a rapid, reversible suppression of gonadotropin secretion. The suppression of pituitary LH secretion by Ganirelix Acetate is more pronounced than that of FSH. |
|
| A449 | Cofetuzumab Featured | Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is usually CHO (Chinese Hamster Ovary) cells. |
|
| A450 | Apamistamab Featured |
|
|
| A451 | Novartis patent anti-CD45 Featured |
|
|
| A452 | Ntx1088 Featured |
|
|
| A453 | GSK-4381562 Featured |
|
|
| A454 | Anti-PVRIG Antibody (COM701) Featured |
|
|
| A455 | Foravirumab Featured | Foravirumab (CR4098) is a monoclonal antibody against rabies virus glycoprotein antigenic site III. |
|
| A456 | Rafivirumab Featured | Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails. |
|
| A457 | Medella patent anti-RAMP-3 Featured |
|
|
| A458 | 19G9 Featured |
|
|
| A459 | Elezanumab Featured | Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism. |
|
| A460 | Anti-RGMC/HFE2 Antibody (DISC-0974) Featured |
|
|
| A461 | Roledumab Featured | Roledumab (LFB-R593) is a human IgG1-κ antibody targeting RHD/CD240D. Roledumab is expressed by YB2/0 rat hybridoma cells. |
|
| A462 | LFB Anti-RhD Featured |
|
|
| A463 | Asclepius Technology patent anti-Robo1 CAR Featured |
|
|
| A464 | Zilovertamab Featured | Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling. |
|
| A465 | Ozuriftamab Featured | Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC. |
|
| A466 | Oncomed patent anti-RSPO1 Featured |
|
|
| A467 | Rosmantuzumab Featured | Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors. |
|
| A468 | Palivizumab Featured | Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice. |
|
| A469 | Motavizumab Featured | Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research. |
|
| A470 | Ozanezumab Featured | Ozanezumab (GSK1223249) is an anti-Nogo-A (neurite outgrowth inhibitor A) monoclonal antibody. Ozanezumab can be used in amyotrophic lateral sclerosis (ALS) and multiple sclerosis research. |
|
| A471 | Atinumab Featured | Atinumab (6A3-IgG4) is an antibody. Teropavimab can be used for the research of spinal cord injury (SCI). |
|
| A472 | Atinumab (NG-101) Featured |
|
|
| A473 | LK-1 Featured |
|
|
| A474 | CDX-0158 Featured |
|
|
| A475 | LOP628 Featured |
|
|
| A476 | Wuhan U. patent anti-Nav1.9 Featured |
|
|
| A477 | Duke anti-NAv1.7 Featured |
|
